Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that focuses on pioneering novel cancer therapies. The company is engaged in the discovery, development, and investigation of cancer treatments, particularly those addressing high unmet medical needs.

msh id	COM:KARYOPHARM
symbol	KPTI
name	Karyopharm Therapeutics Inc.
homepage url	https://www.karyopharm.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	325
crunchbase url	-
linkedin url	-
founders	-

market cap	107.99M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	2.4K
monthly webtraffic growth	-0.31
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.08
growth cost of revenue	0.05
growth depreciation and amortization	-0.77
growth ebitda	0.08
growth ebitda ratio	0.01
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.09
growth gross profit	-0.07
growth gross profit ratio	-0

COM:KARYOPHARM

Karyopharm Therapeutics Inc.

Last Close

0.78

21/11 21:00

Market Cap

107.99M

Beta: -

Volume Today

278.50K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	275.57M
cost of revenue	275.57M
depreciation and amortization	530K
ebitda	-129.01M
ebitda ratio	-0.88
eps	-1.25
eps diluted	-1.25
operating expenses	270.1M
operating income	-129.54M
operating income ratio	-0.89

accounts receivables	20.12M
capital expenditure	-
cash at beginning of period	136.25M
cash at end of period	52.89M
inventory	3.04M
working capital ttm	185.09M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-